|
KMID : 1039320230230010166
|
|
Journal of Liver Cancer
2023 Volume.23 No. 1 p.166 ~ p.176
|
|
|
Use of doxorubicin-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein invasion: a prospective study
|
|
Yu Su-Jong
Lee Yun-Bin
Cho Eun-Ju
Lee Jeong-Hoon
Kim Hyo-Cheol
Chung Jin-Wook
Yoon Jung-Hwan
Kim Yoon-Jun
|
|
|
Abstract
|
|
|
Background/Aim: To evaluate the applicability of transarterial chemoembolization (TACE) treatment with doxorubicin drug-eluting beads (DEBs) in advanced hepatocellular carcinoma (HCC) patients with portal vein invasion (PVI).
Methods: This prospective study was approved by the institutional review board and informed consent was obtained from all participants. A total of 30 HCC patients with PVI received DEB-TACE between 2015 and 2018. The following parameters were evaluated: complications during DEB-TACE, abdominal pain, fever, and laboratory outcomes, including liver function change. Overall survival (OS), time to progression (TTP), and adverse events were also analyzed and assessed.
Results: DEBs measuring 100?300 μm in diameter were loaded with doxorubicin (150 mg per procedure). There were no complications during DEB-TACE and no significant differences in the levels of prothrombin time, serum albumin, or total bilirubin at follow-up compared to baseline. The median TTP was 102 days (95% confidence interval [CI], 42?207 days) and the median OS was 216 days (95% CI, 160?336 days). Three patients (10%) had severe adverse reactions, including transient acute cholangitis (n=1), cerebellar infarction (n=1), and pulmonary embolism (n=1), but no treatment-related death occurred.
Conclusions: DEB-TACE may be a therapeutic option for advanced HCC patients with PVI.
|
|
|
KEYWORD
|
|
|
Carcinoma, hepatocellular, Chemoembolization, therapeutic, Sorafenib, Portal vein
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|